advertisement
Abstract #100515 Published in IGR 23-1
Intraocular Peak Pressure in Patients under Treatment with Fixed Combination of Bimatoprost/ Timolol/ Brimonidine once Daily versus Twice Daily
Susanna BN; Susanna CN; Susanna FN; Mota RT; Barbosa GCS; Lima VL; Susanna RJournal of Glaucoma 2022; 31: e96-e100
PRECIS: We investigate the efficacy of triple-fixed-combination of Bimatoprost/Brimonidine/Timolol once and twice a day, demonstrating higher intraocular pressure reduction with once-a-day use, and discuss possible implications based on previous literature. PURPOSE: To compare the efficacy of fixed combination bimatoprost-timolol-brimonidine (Triplenex ®) instilled once-daily with twice-daily in primary open-angle glaucoma. PATIENTS AND METHODS: Randomized clinical trial at a public eye care institution. Thirty patients with primary open-angle glaucoma were followed-up for three-months. The right and left eyes of these patients were randomly assigned to once-daily, (10:00 PM) or twice-daily, (10:00 AM; 10:00 PM) regimens of fixed combination bimatoprost-timolol-brimonidine. Intraocular pressure peaks were obtained with the water drinking test before the introduction of this medication (basal WDT0), one month (WDT 1), 2 months (WDT2) and 3 months (WDT3) after starting the use of the fixed combination of Bimatoprost/ Timolol/ Brimonidine (Triplenex®). Variation from peak intraocular pressure at WDT3 to peak at WDT0 was compared within groups of two versus once daily regimen. RESULTS: Sixty eyes of 30 patients (age 70.67±9.70▒y) were included in this study. Baseline clinical characteristics were comparable between groups. Mean reduction in peak intraocular pressure from WDT0 to WDT3 was 6.1±6.1▒mmHg (30.5%) in the eyes receiving one drop per day and 4.3 ±5.7▒mmHg (21.5%) in the eyes receiving two drops per day (P=0.023). Mean reduction in peak intraocular pressure considering all WDT was also higher in the group with once-a-day treatment (5.90±6.03▒mmHg vs. 4.46±4.28▒mmHg, P=0.006). CONCLUSION: Fixed combination of bimatoprost 0.01%, brimonidine tartrate 0.15% and timolol maleate 0.5% once-a-day is more effective in reducing peak intraocular pressure as measured by the WDT than twice-a-day dosing.
Department of Ophthalmology, ABC Foundation School of Medicine, Santo André, Brazil.
Full article